Company Overview
Position Overview
We are seeking a Senior Director, Commercial Accounting to lead the establishment and execution of commercial accounting operations as we prepare to launch our first product. This role will be instrumental in building scalable accounting processes and the internal control framework for revenue recognition, inventory and cost of goods sold, third-party logistics (3PL) accounting, and gross-to-net considerations while partnering closely with Commercial, Supply Chain, and Finance leadership.
The ideal candidate brings hands-on experience supporting product launches in biotech or life sciences, thrives in a fast-paced, pre-commercial or early-commercial environment, and can balance technical accounting expertise with cross-functional collaboration.
Responsibilities
Revenue Recognition & Commercial Accounting
- Own and implement ASC 606 revenue recognition policies, procedures, and control activities for product sales.
- Manage the development of a model and oversee accounting processes for gross-to-net reserves (e.g., chargebacks, rebates, returns, Medicaid/Medicare, and other government and commercial programs, as applicable).
- Oversee accounting for the outsourced order-to-cash process, ensuring accurate billing, revenue cut-off, cash application, and reconciliations.
- Prepare and maintain technical accounting memos, internal control narratives, and process documentation to support internal and external audits.
- Collaborate with FP&A, Commercial, Market Access, Supply Chain, Legal, and IT teams to align accounting, forecasting, and operational execution.
- Provide accounting guidance on new commercial initiatives, pricing strategies, and distribution models in a SOX-controlled environment.
- Lead and develop commercial accounting staff and/or external consultants, as appropriate for company size.
- Prepare SEC reporting, audit committee materials, and internal management reporting related to commercial activities.
- Serve as a primary point of contact for external auditors for commercial accounting functions, including walkthroughs, control testing, and issue remediation.
Inventory & COGS
- Own accounting for worldwide commercial and clinical inventory, including costing, overhead rate planning and application, variances, and inventory cost and quantity roll-forwards.
- Direct the review of monthly manufacturing accruals, partner with cross-functional teams to ensure an accurate and timely financial close, and drive process improvements across the accrual close cycle.
- Establish SOX-compliant controls over inventory valuation, reserves, obsolescence, excess inventory, and physical counts.
- Ensure reconciliation and completeness controls between operational systems, 3PL reports, and the general ledger.
- Provide guidance for ERP and 3PL system implementations, including design, testing, internal controls and audit readiness.
Qualifications
- Bachelor’s degree in Accounting or Finance; CPA preferred.
- 10+ years of progressive accounting experience, including experience in a public company subject to SOX 404(b), or equivalent, ideally 5+ years of experience in Commercial Accounting.
- Significant experience in biotech, pharmaceutical, or life sciences, with direct exposure to commercial operations.
- Demonstrated expertise in ASC 606 revenue recognition, inventory accounting, and cost of goods sold.
- Hands-on experience working with 3PLs, CMOs, and distribution partners in a controlled environment.
- Strong understanding of SOX internal controls, documentation standards, and audit processes.
- Experience building or enhancing accounting processes in a lean, high-growth public company.
Knowledge and Skills
- Excellent communication and cross-functional collaboration skills.
- Ability to operate at both a strategic and detailed execution level.
- Experience supporting a first commercial product launch in a public company preferred.
- Experience scaling SOX processes post-commercialization preferred.
E/E/O
Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.
E-Verify
Immunome, Inc. is a participant in E-Verify. Please review the following notices: E-Verify Participation Poster | Right to Work Poster (English) | Right to Work Poster (Spanish).
Skills Required
- Bachelor's degree in Accounting or Finance
- CPA certification
- 10+ years of progressive accounting experience
- Experience in a public company subject to SOX 404(b), or equivalent
- 5+ years of Commercial Accounting experience
- Significant experience in biotech, pharmaceutical, or life sciences with direct exposure to commercial operations
- Expertise in ASC 606 revenue recognition, inventory accounting, and cost of goods sold
- Hands-on experience working with 3PLs, CMOs, and distribution partners in a controlled environment
- Strong understanding of SOX internal controls, documentation standards, and audit processes
- Experience building or enhancing accounting processes in a lean, high-growth public company
- Excellent communication and cross-functional collaboration skills
- Ability to operate at both a strategic and detailed execution level
- Experience supporting a first commercial product launch in a public company
- Experience scaling SOX processes post-commercialization
What We Do
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.
